On this page
Back to topAttovia Therapeutics ATTO
Attovia Therapeutics listed on Nasdaq on 5 Aug 2026 and is not in the S&P 500. It is worth $712 million. Its price history starts on 7 Aug 2026. Its board is not in our data yet.
- Listed
- 5 Aug 2026 on Nasdaq, IPO filings and terms
- Headquarters
- San Carlos, CA
- Market cap
- $712M
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Financial history
Twelve months to 30 Jun 2026, from Attovia Therapeutics' quarterly filings.
Quarters since Sep 2025
- P/E
- -
- No profit over the last four quarters
Quarterly results
Each quarter's revenue, net income and free cash flow.
Sep 2025 to Jun 2026
Not reported for enough quarters.
Not reported for enough quarters.
Not reported for enough quarters.
| Quarter | Revenue | Net income |
|---|---|---|
| Jun 2026 | $450,000 | $-21M |
| Sep 2025 | $360,000 | $-14M |
Attovia Therapeutics' market cap since August 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $690M |
Download Attovia Therapeutics' data as JSON, with the weekly market caps in billions of dollars from 7 Aug 2026.
Board and leadership
Board and officers
Attovia Therapeutics' board is not in our data yet. It listed on 5 Aug 2026 and has not filed a proxy statement. See its 8-K filings.
Owners and trading
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers sold $2.3 million of stock in 1 sale and bought $10.3 million in 2 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 6 Aug 2026Buy | Colin WalshDirector | $8.5M |
| 5 Aug 2026Sale | Colin WalshDirector | $2.3M |
| 5 Aug 2026Buy | Colin WalshDirector | $1.8M |
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
1 large insider sale in the last two years.
Insider sales of $1 million or more, and the largest tenth of Attovia Therapeutics' insider sales.
Events, newest first
- 5 Aug 2026 Colin Walsh sold $2.3MDirector
| Date | Event | Filing |
|---|---|---|
| 5 Aug 2026 | Colin Walsh sold $2.3MDirector | Form 4 |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months. 13F holdings: Attovia Therapeutics listed after the last quarter (30 Jun 2026). The next 13F filings were due by 14 Nov 2026.